

Amendments to the Claims:

1. (Currently Amended) A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide ~~3-13 amino acids in length~~ having a C-terminal amino acid sequence KPV (~~SEQ ID NO: 1~~) selected from the group of peptides consisting of KPV (SEQ ID NO: 1), VKP-Ac-CC-Ac-KPV (SEQ ID NO: 4), HFRWGKPV (SEQ ID NO: 2) and SYSMEHFRWGKPV (SEQ ID NO: 3) in combination with a therapeutically effective amount of a decongestant/antihistamine.
2. (Cancelled)
3. (Previously Presented) The composition of claim 1 wherein said decongestant/antihistamine is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chloropheniramine, bromopheniramine, pheniramine and loratadine.
4. (Previously Presented) The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.
5. (Previously Presented) The composition of claim 4 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithramycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cepodoxime proxetil, clarithromycin, and azithramycin.
6. (Previously Presented) The composition of claim 1 further comprising a therapeutically effective amount of a glucocorticosteroid.
7. (Currently Amended) The composition of claim 6 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and triamcinolone.

8. (Previously Presented) The composition of claim 1 further comprising a therapeutically effective amount of a fungicide.

9. (Previously Presented) The composition of claim 8 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

10. (Currently Amended) The pharmaceutical composition of claim 1 further comprising contained in a carrier.

11. (Previously Presented) The composition of claim 10 wherein the concentration of said peptide is at least  $10^{-12}$ .

12. (Previously Presented) The composition of claim 11 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin, maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, and hydroxymethyl cellulose with glycerin.

13. (Withdrawn) A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV in combination with a therapeutically effective amount of a decongestant/antihistamine and a therapeutically effective amount of a fungicide.

14. (Withdrawn) The pharmaceutical composition of claim 13 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.

15. (Withdrawn) The composition of claim 13 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

16. (Withdrawn) The composition of claim 13 further comprising application of a therapeutically effective amount of an antibiotic.

17. (Withdrawn) The composition of claim 16 wherein said antibiotic is selected from the group consisting of amoxicillin, ampicillin, azithramycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cepodoxime proxetil, clarithromycin, and azithramycin.

18. (Withdrawn) The composition of claim 13 further comprising a therapeutically effective amount of a glucocorticosteroid.

19. (Withdrawn) The composition of claim 18 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, triamcinolone.

20. (Withdrawn) The composition of claim 13 wherein said antihistamine/decongestant is selected from the group consisting of pseudoephedrine, phenylephrine, phenylpropanolamine, chloropheniramine, bromopheniramine, pheniramine and loratadine.

21. (Withdrawn) The pharmaceutical composition of claim 13 further solvated in a carrier.

22. (Withdrawn) The composition of claim 21 wherein the concentration of said peptide is at least  $10^{-12}$ .

23. (Withdrawn) The composition of claim 21 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.

24. (Withdrawn) A method for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV (SEQ ID NO: 1).

25. (Withdrawn) The method of claim 24 wherein the peptide is selected from the group with a C-terminal amino acid sequence consisting of KPV (SEQ ID NO: 1), VPK-Ac-CC-Ac-KPV (SEQ ID NO: 4) , HFRWGKPV (SEQ ID NO: 2) and SYSMEHFRWGKPV(SEQ ID NO: 3).

26. (Withdrawn) The method of claim 24 further comprising application of therapeutically effective amount of a fungicide.

27. (Withdrawn) The method of claim 26 wherein said fungicide is selected consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

28. (Withdrawn) The method of claim 24 further comprising application of a therapeutically effective amount of an antibiotic.

29. (Withdrawn) The method of claim 28 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithramycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cepodoxime proxetil, clarithromycin, and azithramycin.

30. (Withdrawn) The method of claim 24 further comprising application of a therapeutically effective amount of a decongestant/antihistamine.

31. (Withdrawn) The method of claim 28 further said decongestant is selected from the group consisting of pseudoephedrine, phenylephrine, phenylpropanolamine, chloropheniramine, bromopheniramine, pheniramine and loratadine.

32. (Withdrawn) The method of claim 24 further comprising application of a therapeutically effective amount of a glucocorticosteroid.

33. (Withdrawn) The method of claim 32 wherein said glucocorticosteroid is selected from the group consisting of betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, triamcinolone.

34. (Withdrawn) The method of claim 24 wherein said peptide is systemically or topically applied before, during or after surgery performed to treat sinusitis.